[342 Pages Report] The legionnaire disease testing market is projected to register a CAGR of 9% during the forecast period, up from US$ 292 Mn in 2022 to reach a valuation of US$ 819.5 Mn by 2032.
The legionnaire disease testing market is anticipated to show promising growth prospects during the forecast period as a result of growing competition. New competitors are offering a variety of options at reasonable pricing to fulfil the demand for legionnaire disease testing making it more accessible to customers in the global legionnaire disease testing market.
Report Attribute | Details |
---|---|
Estimated Base Year Value (2021) | US$ 267 Million |
Expected Market Value (2022) | US$ 292 Million |
Anticipated Forecast Value (2032) | US$ 819.5 Million |
Projected Growth Rate (2022-2032) | 9% CAGR |
Sales of legionnaire disease testing are expected to rise significantly. In addition to this, sales of legionnaire disease testing are rising on account for US$ 411.3 Mn by 2026. Increasing sales of legionnaire disease testing are also projected to contribute to the growth of the legionnaire disease testing market share.
Increasing public knowledge about effective illness detection and management has resulted from increased government programmes and financing. Furthermore, the worldwide legionnaire disease testing market is being driven by an increase in the need for better diagnostic methods as the prevalence rate rises.
The legionnaire illness testing market may expand as the adoption rate of legionnaire disease testing rises. The legionnaire disease testing market is also predicted to rise due to increased R&D initiatives for technology development for different illnesses.
The shortage of qualified specialists, on the other hand, is likely to stifle the legionnaire disease testing market expansion. Lack of resources and ignorance about infection are also predicted to stymie the sales of legionnaire disease testing market expansion.
Manufacturers in the legionnaire disease testing market get a big platform from which to serve the whole demand for legionnaire disease testing. The worldwide sales of legionnaire disease testing is seeing increased competition. With growing competition, new competitors are offering a variety of options at reasonable pricing, fulfilling the demand for legionnaire disease testing more accessible to customers.
Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the World Health Organization, 75-80% of the population is 50 years old or older, with 65-70% of the population being male. The male population is more susceptible to the demand for legionnaire disease testing than the female population.
Furthermore, the elderly are at a higher risk of legionnaire disease testing and are more likely to get infected. Globally, however, the advancement of innovative testing technologies is increasing. Increased knowledge of present and evolving technology is also helping to boost acceptance of the new testing method, which is projected to open up significant sales of legionnaire disease testing.
However, a scarcity of qualified healthcare providers, as well as a lack of knowledge of the condition and the inability to diagnose it at an early stage, may stymie the demand for legionnaire disease testing market expansion. Furthermore, the absence of improved healthcare facilities may limit the legionnaire disease testing market growth.
The sales of legionnaire disease testing market in Asia-Pacific are predicted to expand rapidly in the next years. This is owing to the existence of a huge population of people who are at high risk. In addition, a lack of knowledge on how to treat infectious diseases is adding to the region's growing population at risk.
The legionnaire disease testing market is predicted to increase rapidly as a result of this. Because of the region's excellent healthcare infrastructure and extensive research and development activities, the North American legionnaire disease testing market is likely to be the most prominent. Due to the availability of qualified researchers and a strong acceptance rate in the area, Europe will rank second in the sales of legionnaire disease testing market.
Due to a scarcity of qualified specialists in the region, the legionnaire disease testing market in Latin America is predicted to rise steadily. Due to a lack of facilities and public knowledge of legionnaire illness, the Middle East and Africa are likely to be the least profitable hence a decline in the demand for legionnaire disease testing.
The report consists of key players, contributing to the legionnaire disease testing market share. It also consists of organic and inorganic growth strategies adopted by market players to improve their market positions. This exclusive report analyzes the competitive landscape and legionnaire disease testing market share acquired by players to strengthen their market position.
Some of the key players present in the global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Report Attribute | Details |
---|---|
Growth rate | CAGR of 9% from 2022 to 2032 |
Base year for estimation | 2021 |
Historical data | 2015 - 2020 |
Forecast period | 2022 - 2032 |
Quantitative units | Revenue in USD Million and CAGR from 2022 to 2032 |
Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis |
Segments covered | Product type, diagnostic test, end user, region |
Regional scope | North America; Western Europe, Eastern Europe, Middle East, Africa, ASEAN, South Asia, Rest of Asia, Australia and New Zealand |
Country scope | U.S.; Canada; Mexico; Germany; U.K.; France; Italy; Spain; Russia; Belgium; Poland; Czech Republic; China; India; Japan; Australia; Brazil; Argentina; Colombia; Saudi Arabia; UAE; Iran; South Africa |
Key companies profiled | Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others |
Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options | Avail of customized purchase options to meet your exact research needs. |
The legionnaire disease testing market is predicted to register a CAGR of 9% during the forecast period.
Key players holding substantial legionnaire disease testing market share include Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others
As per the analysis, the legionnaire disease testing market share is likely to be US$ 411.3 Mn by 2026.
Demand for legionnaire disease testing is likely to rise being driven by an increase in the need for better diagnostic methods as the prevalence rate rises.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast, 2022-2032 4.1. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis, 2017-2021 4.2. Current and Future Market Size Value (US$ Mn) & Volume (Units) Projections, 2022-2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Product Type, 2017-2021 5.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Product Type, 2022-2032 5.3.1. Devices 5.3.2. Polymerase Chain Reaction System 5.3.3. Sequencer System 5.3.4. Test Kits 5.3.5. Assay Based Test Kits 5.3.6. Rapid Test Kits 5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021 5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032 6. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Diagnostic Test 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Diagnostic Test, 2017-2021 6.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Diagnostic Test, 2022-2032 6.3.1. Culture Method 6.3.2. Urinary Antigen Test 6.3.3. Paired Serology 6.3.4. Direct Fluorescent Antibody Stain 6.3.5. Polymerase Chain Reaction 6.3.6. Combination Testing 6.4. Y-o-Y Growth Trend Analysis By Diagnostic Test, 2017-2021 6.5. Absolute $ Opportunity Analysis By Diagnostic Test, 2022-2032 7. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By End User, 2017-2021 7.3. Current and Future Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By End User, 2022-2032 7.3.1. Hospitals 7.3.2. Diagnostic Laboratories 7.3.3. Clinical Research Centers 7.3.4. Academic Institutes 7.3.5. Research Centers 7.3.6. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2017-2021 7.5. Absolute $ Opportunity Analysis By End User, 2022-2032 8. Global Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Mn) & Volume (Units) Analysis By Region, 2017-2021 8.3. Current Market Size Value (US$ Mn) & Volume (Units) Analysis and Forecast By Region, 2022-2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. East Asia 8.3.5. South Asia & Pacific 8.3.6. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country 9.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 9.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Product Type 9.2.3. By Diagnostic Test 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product Type 9.3.3. By Diagnostic Test 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country 10.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 10.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 10.2.1. By Country 10.2.1.1. Mexico 10.2.1.2. Brazil 10.2.1.3. Rest of Latin America 10.2.2. By Product Type 10.2.3. By Diagnostic Test 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product Type 10.3.3. By Diagnostic Test 10.3.4. By End User 10.4. Key Takeaways 11. Europe Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country 11.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 11.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. Italy 11.2.1.3. France 11.2.1.4. U.K. 11.2.1.5. Spain 11.2.1.6. BENELUX 11.2.1.7. Russia 11.2.1.8. Rest of Europe 11.2.2. By Product Type 11.2.3. By Diagnostic Test 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product Type 11.3.3. By Diagnostic Test 11.3.4. By End User 11.4. Key Takeaways 12. East Asia Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country 12.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 12.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Product Type 12.2.3. By Diagnostic Test 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product Type 12.3.3. By Diagnostic Test 12.3.4. By End User 12.4. Key Takeaways 13. South Asia & Pacific Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country 13.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 13.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 13.2.1. By Country 13.2.1.1. India 13.2.1.2. ASEAN 13.2.1.3. Australia and New Zealand 13.2.1.4. Rest of South Asia & Pacific 13.2.2. By Product Type 13.2.3. By Diagnostic Test 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product Type 13.3.3. By Diagnostic Test 13.3.4. By End User 13.4. Key Takeaways 14. MEA Legionnaire Disease Testing Market Analysis 2017-2021 and Forecast 2022-2032, By Country 14.1. Historical Market Size Value (US$ Mn) & Volume (Units) Trend Analysis By Market Taxonomy, 2017-2021 14.2. Market Size Value (US$ Mn) & Volume (Units) Forecast By Market Taxonomy, 2022-2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. Turkey 14.2.1.3. South Africa 14.2.1.4. Rest of MEA 14.2.2. By Product Type 14.2.3. By Diagnostic Test 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product Type 14.3.3. By Diagnostic Test 14.3.4. By End User 14.4. Key Takeaways 15. Key Countries Legionnaire Disease Testing Market Analysis 15.1. U.S. 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Product Type 15.1.2.2. By Diagnostic Test 15.1.2.3. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Product Type 15.2.2.2. By Diagnostic Test 15.2.2.3. By End User 15.3. Mexico 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Product Type 15.3.2.2. By Diagnostic Test 15.3.2.3. By End User 15.4. Brazil 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Product Type 15.4.2.2. By Diagnostic Test 15.4.2.3. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Product Type 15.5.2.2. By Diagnostic Test 15.5.2.3. By End User 15.6. Italy 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Product Type 15.6.2.2. By Diagnostic Test 15.6.2.3. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Product Type 15.7.2.2. By Diagnostic Test 15.7.2.3. By End User 15.8. U.K. 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Product Type 15.8.2.2. By Diagnostic Test 15.8.2.3. By End User 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Product Type 15.9.2.2. By Diagnostic Test 15.9.2.3. By End User 15.10. BENELUX 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Product Type 15.10.2.2. By Diagnostic Test 15.10.2.3. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Product Type 15.11.2.2. By Diagnostic Test 15.11.2.3. By End User 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Product Type 15.12.2.2. By Diagnostic Test 15.12.2.3. By End User 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Product Type 15.13.2.2. By Diagnostic Test 15.13.2.3. By End User 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Product Type 15.14.2.2. By Diagnostic Test 15.14.2.3. By End User 15.15. India 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Product Type 15.15.2.2. By Diagnostic Test 15.15.2.3. By End User 15.16. ASEAN 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Product Type 15.16.2.2. By Diagnostic Test 15.16.2.3. By End User 15.17. Australia and New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Product Type 15.17.2.2. By Diagnostic Test 15.17.2.3. By End User 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Product Type 15.18.2.2. By Diagnostic Test 15.18.2.3. By End User 15.19. Turkey 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Product Type 15.19.2.2. By Diagnostic Test 15.19.2.3. By End User 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Product Type 15.20.2.2. By Diagnostic Test 15.20.2.3. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product Type 16.3.3. By Diagnostic Test 16.3.4. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Beckman Coulter, Inc. 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. Bio-Rad Laboratories, Inc. 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Abbott Laboratories. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. F. Hoffmann-La Roche AG 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Thermo Fischer Scientific, Inc. 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Becton, Dickinson and Company 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Aquacert Ltd 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. BioMérieux SA 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Idexx Laboratories Inc. 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports